AQUINOX PHARMACEUTICALS, INC (35)

Browse by Contract Category

Contracts

Employment Agreement, dated April 14, 2021, by and between Neoleukin Therapeutics, Inc. and Priti Patel (Filed With SEC on March 1, 2022)
Amendment No. 2 to Exclusive Start-Up License Agreement, dated December 15, 2021, by and between the University of Washington and Neoleukin Therapeutics, Inc (Filed With SEC on March 1, 2022)
ATM Equity Offering Sales Agreement, dated November 4, 2021, by and between Neoleukin Therapeutics, Inc. and BofA Securities, Inc (Filed With SEC on November 4, 2021)
Second Amendment to Lease, dated March 24, 2021, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC (Filed With SEC on May 12, 2021)
Purchase Order, dated November 25, 2020, by and between Neoleukin Therapeutics, Inc. and Rigaku Americas Corporation (Filed With SEC on March 25, 2021)
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 12, 2020)
Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August 5, 2019 (Filed With SEC on August 6, 2019)
Neoleukin Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on May 14, 2021)
Amendment No. 1 to Exclusive Start-Up License Agreemen (Filed With SEC on March 25, 2021)
Executive Employment Agreement, dated September 29, 2020, by and between Neoleukin Therapeutics, Inc., and Holly Vance (Filed With SEC on March 25, 2021)
First Amendment to Lease, dated November 5, 2020, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC (Filed With SEC on March 25, 2021)
Forms of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice for Registrants 2014 Equity Incentive Plan (Filed With SEC on August 12, 2020)
First Amendment, dated June 18, 2020, to Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on August 12, 2020)
Form of Pre-Funded Warrant (Filed With SEC on July 2, 2020)
Underwriting Agreement, dated July 1, 2020 (Filed With SEC on July 2, 2020)
Neoleukin Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on May 6, 2020)
Employment Agreement, dated March 16, 2020, by and between Neoleukin Therapeutics, Inc. and Robert Ho (Filed With SEC on May 6, 2020)
Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G. Drachman (Filed With SEC on April 17, 2020)
Lease Agreement, dated December 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on March 12, 2020)
Form of Pre-Funded Warrant (Filed With SEC on December 19, 2019)
Underwriting Agreement, dated December 17, 2019 (Filed With SEC on December 19, 2019)
Exchange Agreement, dated December 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P (Filed With SEC on December 19, 2019)
Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan, as amended November 12, 2019 (Filed With SEC on November 14, 2019)
Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on November 13, 2019)
Exclusive Start-Up License Agreement, dated July 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)
Amendment No. 1 to the Facility Use Agreement, dated April 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)
Facility Use Agreement, dated December 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)
Transition Retention Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamram Alam (Filed With SEC on August 6, 2019)
Employment Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Jonathan G. Drachman (Filed With SEC on August 6, 2019)
Separation Agreement and Release, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J. Main (Filed With SEC on August 6, 2019)
Form of Lock-Up Agreement, by each of the parties named in each agreement therein (Filed With SEC on August 6, 2019)
Form of Support Agreement, by and among Aquinox Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on August 6, 2019)
Executive Employment Agreement Amendment for David Main (Filed With SEC on August 1, 2019)
Executive Employment Agreement Amendment for Kamran Alam (Filed With SEC on August 1, 2019)
Early Termination Agreement by and between Aquinox Pharmaceuticals (Canada), Inc. and Astellas US LLC, effective as of November 8, 2018 (Filed With SEC on March 7, 2019)